Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1997 21
1998 72
1999 63
2000 65
2001 81
2002 95
2003 116
2004 105
2005 109
2006 99
2007 121
2008 141
2009 138
2010 129
2011 134
2012 126
2013 133
2014 141
2015 136
2016 142
2017 129
2018 128
2019 130
2020 84
2021 112
2022 92
2023 77
2024 71
2025 30

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,785 results

Results by year

Filters applied: . Clear all
Page 1
Abacavir.
Foster RH, Faulds D. Foster RH, et al. Drugs. 1998 May;55(5):729-36; discussion 737-8. doi: 10.2165/00003495-199855050-00018. Drugs. 1998. PMID: 9585869 Review.
Resistance to abacavir develops relatively slowly. Cross-resistance between abacavir and didanosine, zalcitabine or lamivudine, but not zidovudine or stavudine, has been reported in vitro. Abacavir has good oral bioavailability, as demonstrated in animals, an …
Resistance to abacavir develops relatively slowly. Cross-resistance between abacavir and didanosine, zalcitabine or lamivudine …
Abacavir-induced liver toxicity.
Pezzani MD, Resnati C, Di Cristo V, Riva A, Gervasoni C. Pezzani MD, et al. Braz J Infect Dis. 2016 Sep-Oct;20(5):502-4. doi: 10.1016/j.bjid.2016.03.002. Epub 2016 Apr 4. Braz J Infect Dis. 2016. PMID: 27054757 Free PMC article. Review.
Abacavir-induced liver toxicity is a rare event almost exclusively occurring in HLA B*5701-positive patients. Herein, we report one case of abnormal liver function tests occurring in a young HLA B*5701-negative woman on a stable nevirapine-based regimen with no history of …
Abacavir-induced liver toxicity is a rare event almost exclusively occurring in HLA B*5701-positive patients. Herein, we report one c …
An up-to-date evaluation of dolutegravir/abacavir/lamivudine for the treatment of HIV.
Christensen BL, Tan DH. Christensen BL, et al. Expert Opin Pharmacother. 2022 Mar;23(4):439-446. doi: 10.1080/14656566.2022.2029409. Epub 2022 Jan 24. Expert Opin Pharmacother. 2022. PMID: 35073817 Review.
The fixed dose combination of dolutegravir (DTG), abacavir (ABC), and lamivudine (3TC) is a convenient, well tolerated, and highly effective option for treating HIV infection and remains a first line therapy across several prominent guidelines. ...
The fixed dose combination of dolutegravir (DTG), abacavir (ABC), and lamivudine (3TC) is a convenient, well tolerated, and highly ef …
Abacavir and cardiovascular disease: A critical look at the data.
Llibre JM, Hill A. Llibre JM, et al. Antiviral Res. 2016 Aug;132:116-21. doi: 10.1016/j.antiviral.2016.05.015. Epub 2016 May 31. Antiviral Res. 2016. PMID: 27260856 Review.
Most HIV-infected subjects will receive a treatment regimen including abacavir or tenofovir. Therefore, clarifying if there is an increased risk of acute myocardial infarction (AMI) among those exposed to abacavir is of the utmost importance. ...A critical review of …
Most HIV-infected subjects will receive a treatment regimen including abacavir or tenofovir. Therefore, clarifying if there is an inc …
Abacavir hypersensitivity reaction: an update.
Hughes CA, Foisy MM, Dewhurst N, Higgins N, Robinson L, Kelly DV, Lechelt KE. Hughes CA, et al. Ann Pharmacother. 2008 Mar;42(3):387-96. doi: 10.1345/aph.1K522. Epub 2008 Feb 26. Ann Pharmacother. 2008. PMID: 18303141 Review.
Patch testing may improve the diagnosis and confirmation of abacavir HSR, but it remains experimental. Clinical management is aimed at supportive therapy and discontinuation of abacavir. Rechallenge with abacavir is contraindicated due to the risk of precipit …
Patch testing may improve the diagnosis and confirmation of abacavir HSR, but it remains experimental. Clinical management is aimed a …
Abacavir/dolutegravir/lamivudine single-tablet regimen: a review of its use in HIV-1 infection.
Greig SL, Deeks ED. Greig SL, et al. Drugs. 2015 Apr;75(5):503-14. doi: 10.1007/s40265-015-0361-6. Drugs. 2015. PMID: 25698454 Review.
A fixed-dose, single-tablet regimen comprising the integrase strand transfer inhibitor (INSTI) dolutegravir and the nucleos(t)ide reverse transcriptase inhibitors (NRTIs) abacavir and lamivudine (abacavir/dolutegravir/lamivudine; Triumeq) is now available for the tr …
A fixed-dose, single-tablet regimen comprising the integrase strand transfer inhibitor (INSTI) dolutegravir and the nucleos(t)ide reverse tr …
Safety and efficacy of abacavir for treating infants, children, and adolescents living with HIV: a systematic review and meta-analysis.
Jesson J, Saint-Lary L, Revegue MHDT, O'Rourke J, Townsend CL, Renaud F, Penazzato M, Leroy V. Jesson J, et al. Lancet Child Adolesc Health. 2022 Oct;6(10):692-704. doi: 10.1016/S2352-4642(22)00213-9. Epub 2022 Sep 2. Lancet Child Adolesc Health. 2022. PMID: 36058225 Free PMC article.
BACKGROUND: Abacavir is a nucleoside reverse transcriptase inhibitor recommended in paediatric HIV care. ...Data from 24 265 participants were included, of whom 7236 (30%) received abacavir. Abacavir hypersensitivity reaction was reported in nine (38%) studie …
BACKGROUND: Abacavir is a nucleoside reverse transcriptase inhibitor recommended in paediatric HIV care. ...Data from 24 265 particip …
Abacavir hypersensitivity.
Abel S, Paturel L, Cabié A. Abel S, et al. N Engl J Med. 2008 Jun 5;358(23):2515; author reply 2515-6. N Engl J Med. 2008. PMID: 18536095 No abstract available.
Abacavir + dolutegravir + lamivudine for the treatment of HIV.
Comi L, Maggiolo F. Comi L, et al. Expert Opin Pharmacother. 2016 Oct;17(15):2097-106. doi: 10.1080/14656566.2016.1232387. Epub 2016 Sep 13. Expert Opin Pharmacother. 2016. PMID: 27616133 Review.
Dolutegravir (DTG) in combination with abacavir/lamivudine (ABC/3TC) is one of these preferred regimens in multiple clinical scenarios, including treatment-naive and treatment-experienced patients. ...
Dolutegravir (DTG) in combination with abacavir/lamivudine (ABC/3TC) is one of these preferred regimens in multiple clinical scenario …
Abacavir use is associated with increased prothrombin conversion.
Yan Q, Huang S, van der Heijden W, Ninivaggi M, van de Wijer L, de Laat-Kremers R, Van der Ven AJ, de Laat B, de Mast Q. Yan Q, et al. Front Immunol. 2023 Apr 14;14:1182942. doi: 10.3389/fimmu.2023.1182942. eCollection 2023. Front Immunol. 2023. PMID: 37122705 Free PMC article.
There is ongoing debate as to whether abacavir (ABC) increases the risk for cardiovascular disease(CVD) in people living with HIV (PLHIV) and the mechanisms underlying this possible association. ...
There is ongoing debate as to whether abacavir (ABC) increases the risk for cardiovascular disease(CVD) in people living with HIV (PL …
2,785 results